Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
StockNews.AI · 2 hours
AI Summary
New SENTRY Phase 3 data indicate rapid, deep spleen volume reductions with selinexor plus ruxolitinib in myelofibrosis, and a post-hoc SVR35 analysis suggests such spleen response may predict overall survival. The EHA abstract was named a Late-Breaking Oral Session, underscoring potential differentiation for KPTI's MF program and potential long-term value if the OS signal remains durable.
Sentiment Rationale
Positive data signals and top-session acknowledgement can lift sentiment and valuation expectations; risk remains until OS durability is proven.
Trading Thesis
Bullish on KPTI over 6–12 months if OS signal holds.
Market-Moving
- EHA presentation on June 14 could trigger intraday moves.
- OS signal from SVR35 may bolster valuation if confirmed.
- Phase 3 SENTRY top-6 abstract could renew MF program attention.
- Near-term catalysts hinge on durability of OS signal and data readouts.
Key Facts
- SENTRY Phase 3: selinexor plus ruxolitinib in MF; oral at EHA June 14.
- Post-hoc SVR35 analysis links 35% spleen reduction to potential OS.
- Results show rapid, deep, sustained spleen reductions and manageable safety.
- EHA abstract selected among top six Late-Breaking Oral Sessions.
- MF program expansion potential if OS signal holds; readouts expected 2026.
Companies Mentioned
- Karyopharm Therapeutics Inc. (KPTI): Phase 3 SENTRY results may drive on-trial momentum; EHA data release could spark near-term stock movement.
Industry News
Industry News: Reports upcoming conference data and a potential OS signal for a cancer therapy, informing near-term equity sentiment and longer-term value hinge on durability of survival benefit.